Carboplatin News and Research

RSS
Carboplatin is a chemotherapy drug used against some forms of cancer (mainly ovarian carcinoma, lung, head and neck cancers).
New model can predict the risk of adverse side effects of cancer treatment

New model can predict the risk of adverse side effects of cancer treatment

Combination therapy improves survival rates for women with aggressive endometrial cancer

Combination therapy improves survival rates for women with aggressive endometrial cancer

International trial shows better option for treating people with inoperable anal cancer

International trial shows better option for treating people with inoperable anal cancer

Study finds carboplatin-paclitaxel as the optimal chemotherapy for anal cancer

Study finds carboplatin-paclitaxel as the optimal chemotherapy for anal cancer

Study compares cediranib plus olaparib and standard of care therapy for platinum-sensitive ovarian cancer

Study compares cediranib plus olaparib and standard of care therapy for platinum-sensitive ovarian cancer

Addition of monoclonal antibody to trimodality therapy offers no benefit in HER2 over expressing esophageal cancer

Addition of monoclonal antibody to trimodality therapy offers no benefit in HER2 over expressing esophageal cancer

Durvalumab plus chemotherapy improved overall survival rate for mesothelioma patients

Durvalumab plus chemotherapy improved overall survival rate for mesothelioma patients

Scientists find gene signature for poor response to standard therapy in rare uterine cancer

Scientists find gene signature for poor response to standard therapy in rare uterine cancer

Drug improves effectiveness of chemotherapy in ovarian cancer patients

Drug improves effectiveness of chemotherapy in ovarian cancer patients

Trial of cancer drug OxaliTex promises lower toxicity and more robust action

Trial of cancer drug OxaliTex promises lower toxicity and more robust action

Administering immunotherapy alongside chemoradiation for advanced NSCLC appears to be safe and tolerable

Administering immunotherapy alongside chemoradiation for advanced NSCLC appears to be safe and tolerable

NCCN ORP plans to support phase II randomized trial for lung cancer patients

NCCN ORP plans to support phase II randomized trial for lung cancer patients

Version of an antibiotic drug extends survival in mice with lethal pediatric brain tumors

Version of an antibiotic drug extends survival in mice with lethal pediatric brain tumors

Study links FAK protein to chemotherapy resistance in ovarian cancer

Study links FAK protein to chemotherapy resistance in ovarian cancer

Nab-Paclitaxel drug combo reduces risk of  breast cancer recurrence

Nab-Paclitaxel drug combo reduces risk of breast cancer recurrence

Study links high number of copies of chromosomal region to chemotherapeutic drug resistance

Study links high number of copies of chromosomal region to chemotherapeutic drug resistance

Cause of cancer is 'written' in our DNA as unique 'fingerprints'

Cause of cancer is 'written' in our DNA as unique 'fingerprints'

IASLC 2019 Small Cell Lung Cancer Meeting focuses on immunotherapy and patient perspective

IASLC 2019 Small Cell Lung Cancer Meeting focuses on immunotherapy and patient perspective

New combination treatment shows promise for common brain tumor in children

New combination treatment shows promise for common brain tumor in children

Clinigen, Accord Healthcare extend exclusive European clinical trial supply agreement

Clinigen, Accord Healthcare extend exclusive European clinical trial supply agreement

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.